Baxter International Infusion Therapies & Platforms revenue
Infusion Therapies & Platforms revenue at Baxter International came to $1.8B for the quarter to 30 Sep 2026, up 5.3% from a year earlier.
As Baxter International reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.
By quarter
| Period ending | Infusion Therapies & Platforms revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $1.8B | up 5.3% | 29 Oct 2026 |
| 30 Jun 2026 | $1.7B | up 5.8% | 30 Jul 2026 |
| 30 Sep 2025 | $1.7B | — | 4 Nov 2025 |
| 30 Jun 2025 | $1.6B | — | 5 Aug 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Baxter International: Infusion Therapies & Technologies revenue · Care & Connectivity Solutions revenue · Advanced Surgery revenue · Drug Compounding revenue · Front Line Care revenue · Injectables & Anesthesia revenue · Medical Products & Therapies revenue · Healthcare Systems & Technologies revenue · Pharmaceuticals revenue · United States revenue · International revenue · financial statements
Every KPI and segment of BAX, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
